Figure 2.
| Fever | (+) | (+) | (+) | (+) | (+) | (−) | (+) | (+) | (−) | (+) | (−) | |
| Hypoxia | (+) | (+) | (+) | (+) | (+) | (+) | (+) | (+) | (+) | (+) | (−) | |
| Lymphocyte absolute count (×109/L) | 0.14 | 0.19 | 0.28 | 0.12 | 0.31 | 0.09 | 0.22 | 0.27 | 0.16 | 0.15 | ND | |
| C-reactive protein level (mg/L) | 141 | 87 | 118 | ND | 162 | 82 | 124 | 106 | 70 | 84 | <3 | |
| Ferritin level (µg/L) | 849 | 1154 | ND | 7670 | 4242 | 4345 | 3100 | 1070 | 791 | 791 | ND | |
| Remdesivir | 10 d | (−) | 5 d | 5 d | (−) | 5 d | 5 d | 5 d | (−) | 5 d | (−) | |
| Corticosteroidsc | 5 d | 10 d | 10 d | 10 d | PDN Taper | + + + | 10 d | PDN taper + | PDN taper + | PDN taper + | + | |
| CP | 2 U | (−) | 2U | (−) | (−) | 2 U | 2 U | (−) | (−) | 2 U | (−) | |
| Vax-plasma | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | 2 U | 1 U |
| Day 0 | Day 8-21 hospitalization | Day 28-38 hospitalization | Day 40-48 hospitalization | Day 78-90 hospitalization | Day 97-109 hospitalizationd | Day 195-200 hospitalization | Day 226-235 hospitalizatione | Day 247-254 hospitalization | Day 262-264 hospitalization | Day 269-276 hospitalization | Day 305 follow-up | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SARS-CoV-2 PCR |
(+) | ND | ND | (+) | (+) | (+) | (+) | (+) | (+) | (+) | (+) | (−) |
| SARS-CoV-2 nudeocapsid antibody | ND | ND | ND | ND | (−) | (−/+)f | (−/+)f | (+) | (+) | (−) | ND | |
| SARS-CoV-2 spike antibody (U/mL) | ND | ND | ND | ND | ND | ND | 1.9 | ND | ND | 2.9–4.1g/>250>250h | >250 | |
| SARS-CoV-2 neutralizing antibody | ND | ND | ND | ND | ND | ND | ND | ND | ND | (−)i/286j | ND |
COP, cryptogenic organizing pneumonia; COVID-19, coronavirus disease 2019; CP, convalescent plasma; ND, no data; PCR, polymerase chain reaction; PDN, prednisone; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; U, units.
SARS-CoV-2 PCR, Cobas SARS-CoV-2 assay (Roche Molecular Systems, Inc.); SARS-CoV-2 nucleocapsid antibody, Roche Elecsys Anti-SARS-CoV-2 Reagent assay (Roche Diagnostics); SARS-CoV-2 spike antibody, SARS-CoV-2 spike glycoprotein antibody (Roche Elecsys Anti-SARS-CoV-2 S Reagent assay from Roche Diagnostics); SARS-CoV-2 neutralizing antibody, IMMUNO-COV.
Patients received dexamethasone initially between 5 and 10 d and then PDN at different doses after the diagnosis of COP.
Admission was complicated by aspiration pneumonia and COP. PDN 20 mg per day was initiated and then tapered down slowly.
The patient required mechanical ventilation, and nasopharynx and bronchoalveolar lavage samples resulted positive for SARS-CoV-2.
SARS-CoV-2 nucleocapsid antibody test results were negative before receiving CP and then turned positive after receiving two units of high-titer CP.
SARS-CoV-2 spike protein antibody test results after receiving the first and second unit of high-titer CP.
SARS-CoV-2 spike protein antibody test results after receiving the first and second unit of super high-titer CP (Vax-plasma).
SARS-CoV-2 neutralizing antibodies after receiving two units of high-titer CP.
SARS-CoV-2 neutralizing antibodies after receiving two units of super high-titer CP (Vax-plasma).